165 related articles for article (PubMed ID: 28126425)
1. Magnetic Resonance Imaging Findings in Patients With Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome.
Li X; Yang X; Xu D; Li Q; Kong X; Lu Z; Bai T; Xu K; Ye J; Song Y
Clin Gastroenterol Hepatol; 2017 Jun; 15(6):955-957. PubMed ID: 28126425
[No Abstract] [Full Text] [Related]
2. Clinical characteristics, CT signs, and pathological findings of Pyrrolizidine alkaloids-induced sinusoidal obstructive syndrome: a retrospective study.
Liu F; Rong X; Guo H; Xu D; Liu C; Meng L; Yang X; Guo T; Kan X; Song Y
BMC Gastroenterol; 2020 Feb; 20(1):30. PubMed ID: 32019495
[TBL] [Abstract][Full Text] [Related]
3. Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome.
Gao H; Ruan JQ; Chen J; Li N; Ke CQ; Ye Y; Lin G; Wang JY
Drug Des Devel Ther; 2015; 9():4861-8. PubMed ID: 26346783
[TBL] [Abstract][Full Text] [Related]
4. Tusanqi and hepatic sinusoidal obstruction syndrome.
Wang JY; Gao H
J Dig Dis; 2014 Mar; 15(3):105-7. PubMed ID: 24528632
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Analysis of CT Images in Patients with Pyrrolizidine Alkaloid-Induced Sinusoidal Obstruction Syndrome.
Wang C; Wu X; Xie W; Ren X; Zhang W; Xu J
Sci Rep; 2019 Feb; 9(1):2179. PubMed ID: 30778132
[TBL] [Abstract][Full Text] [Related]
6. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
Zhuge Y; Liu Y; Xie W; Zou X; Xu J; Wang J;
J Gastroenterol Hepatol; 2019 Apr; 34(4):634-642. PubMed ID: 30669184
[TBL] [Abstract][Full Text] [Related]
7. [Veno-occlusive disease after prolonged treatment with senecionine (Hemoluol)].
Bensaude RJ; Monegier du Sorbier C; Jonville-Bera AP; Autret E; Ouyahya F; Metman EH
Gastroenterol Clin Biol; 1998 Mar; 22(3):363-4. PubMed ID: 9762228
[No Abstract] [Full Text] [Related]
8. First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans.
Yang M; Ruan J; Gao H; Li N; Ma J; Xue J; Ye Y; Fu PP; Wang J; Lin G
Arch Toxicol; 2017 Dec; 91(12):3913-3925. PubMed ID: 28620673
[TBL] [Abstract][Full Text] [Related]
9. [Clinicopathological analysis of 16 cases of pyrrolizidine alkaloids-associated hepatic sinusoidal obstruction syndrome].
Li YS; Bao J; Xu Y; Wang TL
Zhonghua Gan Zang Bing Za Zhi; 2020 Apr; 28(4):332-337. PubMed ID: 32403886
[No Abstract] [Full Text] [Related]
10. Diagnostic performance of Contrast-enhanced CT in Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstructive Syndrome.
Kan X; Ye J; Rong X; Lu Z; Li X; Wang Y; Yang L; Xu K; Song Y; Hou X
Sci Rep; 2016 Nov; 6():37998. PubMed ID: 27897243
[TBL] [Abstract][Full Text] [Related]
11. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes.
Yang XQ; Ye J; Li X; Li Q; Song YH
World J Gastroenterol; 2019 Jul; 25(28):3753-3763. PubMed ID: 31391770
[TBL] [Abstract][Full Text] [Related]
12. Comfrey herb tea and hepatic veno-occlusive disease.
Ridker PM; McDermott WV
Lancet; 1989 Mar; 1(8639):657-8. PubMed ID: 2564469
[No Abstract] [Full Text] [Related]
13. Hepatic veno-occlusive disease associated with toxicity of pyrrolizidine alkaloids in herbal preparations.
Chen Z; Huo JR
Neth J Med; 2010 Jun; 68(6):252-60. PubMed ID: 20558855
[TBL] [Abstract][Full Text] [Related]
14. Development of a Drum Tower Severity Scoring (DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
Wang X; Zhang W; Zhang M; Zhang F; Xiao J; Yin Q; Han H; Li T; Lin G; Zhuge Y
Hepatol Int; 2022 Jun; 16(3):669-679. PubMed ID: 35023026
[TBL] [Abstract][Full Text] [Related]
15. Gadoxetic Acid-Enhanced Hepatobiliary-Phase Magnetic Resonance Imaging for Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome and Association with Liver Function.
Guo T; Li X; Yang X; Kong X; Liu H; Bai T; Xu K; Ye J; Song Y
Sci Rep; 2019 Feb; 9(1):1231. PubMed ID: 30718698
[TBL] [Abstract][Full Text] [Related]
16. Hepatic veno-occlusive disease in newborn infant of a woman drinking herbal tea.
Roulet M; Laurini R; Rivier L; Calame A
J Pediatr; 1988 Mar; 112(3):433-6. PubMed ID: 3346784
[No Abstract] [Full Text] [Related]
17. [Veno-occlusive liver disease due to intake of Senecio vulgaris tea].
Ortiz Cansado A; Crespo Valadés E; Morales Blanco P; Sáenz de Santamaría J; González Campillejo JM; Ruiz Téllez T
Gastroenterol Hepatol; 1995 Oct; 18(8):413-6. PubMed ID: 7584780
[TBL] [Abstract][Full Text] [Related]
18. Direct Intrahepatic Portocaval Shunt for Sinusoidal Obstruction Syndrome Associated with Hepatotoxicity of Pyrrolizidine Alkaloids.
Luo S; Chu J; Huang H; Yao K
Biomed Res Int; 2018; 2018():9804582. PubMed ID: 30009181
[TBL] [Abstract][Full Text] [Related]
19. Plateletcrit for predicting prognosis in patients with hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloid.
Tu H; Li M; Chen Z; Zhao J; Wang H; Qian J; Wei C; Yang Y; Zhu Y; Zuo L
J Clin Lab Anal; 2022 Feb; 36(2):e24240. PubMed ID: 35034375
[TBL] [Abstract][Full Text] [Related]
20. An unexpected cause of an infiltrative liver mass.
Ng V; Tran TT; Sundaram V
Gastroenterology; 2014 Aug; 147(2):e12-3. PubMed ID: 24973685
[No Abstract] [Full Text] [Related]
[Next] [New Search]
